Caroline M. Tanner

San Francisco VA Medical Center — United States

Medicine · Health Sciences

97h-index42.5kcitations454works33.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Parkinson's Disease Mechanisms and Treatments(306), Neurological disorders and treatments(129), Autism Spectrum Disorder Research(42), Nuclear Receptors and Signaling(37), Botulinum Toxin and Related Neurological Disorders(34)

Publications451 total

Environmental toxicants and Parkinson's disease: recent evidence, risks, and prevention opportunities
The Lancet Neurology·2025· 9 cited
Prognostic Value of Parkinson's Disease Subtypes in the <scp>LABS</scp>‐<scp>PD</scp> Cohort: Functional Ability, Quality of Life and Mortality
Movement Disorders Clinical Practice·2025Open Access
Trichloroethylene and Parkinson Disease
Neurology·2025
Stable two-year longitudinal clinical outcomes in LRRK2 G2019S non-manifest carriers in a remote nationwide study
Parkinsonism & Related Disorders·2025Open Access
Improving Prediction of Falls and Cognitive Impairment in Parkinson Disease: Protocol for a Decentralized Observational Study
JMIR Research Protocols·2025Open Access
Care partner needs in Parkinson's disease: A systematic review of qualitative and quantitative data
Journal of Parkinson s Disease·2025· 1 citedOpen Access
Neuronal α‐Synuclein Disease Stage Progression over 5 Years
Movement Disorders·2025· 8 citedOpen Access
Falls during a remote observational Parkinson's disease study: AT-HOME PD2 initial results
Parkinsonism & Related Disorders·2025
Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial
Neuropsychopharmacology·2025· 12 citedOpen Access
Perspectives on Clinical Research Participation Among Hispanic and NonHispanic Participants in an Online Research Study (P4-5.022)
Neurology·2025
Evolving Perspectives on α-Synuclein Testing
JAMA Neurology·2025· 1 cited
Improving Prediction of Falls and Cognitive Impairment in Parkinson Disease: Protocol for a Decentralized Observational Study (Preprint)
2025
<i>LRRK2</i> -associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterization
Brain Communications·2025· 8 citedOpen Access
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha‐Synuclein Disease
Annals of Neurology·2024· 8 citedOpen Access
Impact of dopamine deficiency and REM sleep behavior disorder on cognition in early neuronal synuclein disease with hyposmia
2024Open Access
Smell testing to identify early alpha-synucleinopathy among people with dream enactment behavior
2024Open Access
Validation of Parkinson's Disease Ascertainment in the Veterans Administration Electronic Medical Record
Movement Disorders·2024· 10 citedOpen Access
Parkinson’s Disease
New England Journal of Medicine·2024· 2 cited
Eleven Years of Change: Disease Progression in Biomarker-Defined Sporadic Parkinson’s Disease
2024Open Access
Cross‐Sectional and Prospective Associations between Parkinsonism and Parkinson's Disease with Frailty in Latin America
Movement Disorders Clinical Practice·2024· 1 citedOpen Access
page 1 of 23Next →

Frequent Co-authors

Andrew Siderowf(8), Kenneth Marek(8), Tanya Simuni(8), G. Webster Ross(8), J. William Langston(8), Robert D. Abbott(8), Helen Petrovitch(8), Brit Mollenhauer(7), Mark Frasier(7), Lon R. White(7), Kamal Masaki(7), Daniel Weintraub(7), Danna Jennings(6), Todd Sherer(6), John Seibyl(6), Andrew Singleton(6), Joseph Jankovic(6), Samuel M. Goldman(6), Connie Marras(6), Tatiana Foroud(6)